Chemomab Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Net Income	-13.95	-24.22	-27.65	-12.48	-5.95	Upgrade
Depreciation & Amortization	0.05	0.07	0.06	0.03	0.02	Upgrade
Stock-Based Compensation	0.62	1.49	3.21	2.02	0.13	Upgrade
Change in Accounts Receivable	-0.49	0.9	-0.06	-2.06	-0.1	Upgrade
Change in Accounts Payable	0.15	-1.17	0.35	1.18	0.07	Upgrade
Change in Other Net Operating Assets	-1.77	-0.68	3.72	-1.07	0.59	Upgrade
Operating Cash Flow	-15.39	-23.61	-20.37	-12.37	-5.24	Upgrade
Capital Expenditures	-	-0	-0.07	-0.24	-0.04	Upgrade
Sale of Property, Plant & Equipment	-	-	-	1	-	Upgrade
Investment in Securities	2.3	15.88	19.6	-45.95	-0.02	Upgrade
Other Investing Activities	-	-	-	0	-	Upgrade
Investing Cash Flow	2.3	15.88	19.53	-45.19	-0.06	Upgrade
Issuance of Common Stock	9.87	3.5	0.41	58.65	1.25	Upgrade
Repurchase of Common Stock	-	-	-1.22	-	-	Upgrade
Other Financing Activities	-	-	-	2.43	-	Upgrade
Financing Cash Flow	9.87	3.5	-0.81	61.07	4.75	Upgrade
Net Cash Flow	-3.22	-4.23	-1.65	3.51	-0.55	Upgrade
Free Cash Flow	-15.39	-23.61	-20.44	-12.61	-5.28	Upgrade
Free Cash Flow Per Share	-3.43	-8.04	-7.18	-4.86	-3.09	Upgrade
Cash Income Tax Paid	-	-0.19	-0.35	-	-	Upgrade
Levered Free Cash Flow	-10.86	-15.49	-10.87	-6.07	-2.56	Upgrade
Unlevered Free Cash Flow	-10.86	-15.49	-10.87	-6	-2.56	Upgrade
Change in Working Capital	-2.11	-0.95	4.01	-1.95	0.56	Upgrade

Updated Nov 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q